APOE4 Homozygous Alzheimer’s Disease (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Alzheimer's disease (AD) is a progressive neurodegenerative disease associated with cognitive decline and is the most common form of dementia in the elderly. Approximately 13% of people over the age of 65 and 45% over the age of 85 are estimated to have AD. The imbalance between the production and clearance of amyloid-β (Aβ) peptides in the brain results in the accumulation and aggregation of Aβ. The toxic Aβ aggregates in the form of soluble Aβ oligomers, intraneuronal Aβ, and amyloid plaques injure synapses and ultimately cause neurodegeneration and dementia. The toxicity of Aβ seems to depend on the presence of microtubule-associated protein tau, the hyperphosphorylated forms of which aggregate and deposit in AD brains as neurofibrillary tangles. Aβ is composed of 40 or 42 amino acids and is generated through proteolytic cleavage of the amyloid precursor protein. Early-onset familial AD, which typically develops before the age of 65 years and accounts for only a small portion (<1%) AD cases, is primarily caused by overproduction of Aβ owing to mutations in either the APP gene or genes encoding presenilin 1 (PSEN1) or presenilin 2 (PSEN2), essential components of the γ-secretase complexes responsible for cleavage and release of Aβ.

·       The ε4 allele of the apolipoprotein E (APOE) gene is the strongest risk factor for LOAD.

·       The human APOE gene exists as three polymorphic alleles ε2, ε3, and ε4, which have a worldwide frequency of 8.4%, 77.9%, and 13.7%, respectively. However, the frequency of the ε4 allele is dramatically increased to ~40% in patients with AD.

 

Thelansis’s “APOE4 Homozygous Alzheimer’s Disease (AD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential APOE4 Homozygous Alzheimer’s Disease (AD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of APOE4 Homozygous Alzheimer’s Disease (AD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

APOE4 Homozygous Alzheimer’s Disease (AD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: APOE4 Homozygous Alzheimer’s Disease (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: APOE4 Homozygous Alzheimer’s Disease (AD), APOE4 Homozygous Alzheimer’s Disease (AD) market outlook, APOE4 Homozygous Alzheimer’s Disease (AD) competitive landscape, APOE4 Homozygous Alzheimer’s Disease (AD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)